文献速递肝肾功能剂量调整特殊人群用药药物相互作用

阿哌沙班PBPK模型预测药物相互作用、肾损伤及儿科人群场景

Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations.
PubMed 文献 · Br J Clin Pharmacol · 2021-05-05

本研究在SimCYP中构建并验证了阿哌沙班全身生理药代动力学(PBPK)模型,并扩展至肾损伤和儿科人群,预测阿哌沙班单独及联合相互作用药物时的药代动力学。模型成功预测了肾损伤各组的倍数变化,抑制性药物相互作用与肾损伤对阿哌沙班暴露增加有协同效应;对于小于1岁的婴儿,体重归一化清除率随体重增加而增加,新生儿AUC高于1岁以上儿童。

要点

  • PBPK模型可预测阿哌沙班在肾损伤及儿科人群中的药代动力学。
  • 抑制性药物相互作用与肾损伤对阿哌沙班暴露有协同增加效应。
  • 小于1岁婴儿中药物相互作用效应可能减弱而肾损伤效应可能增强。

核心结论

  • 该研究提供了一种合理方法,用于估计特殊复杂情况下首次使用阿哌沙班的剂量调整。

研究设计与样本

  • 在SimCYP中构建全身阿哌沙班PBPK模型,并在健康成人(伴或不伴相互作用药物)中验证,随后扩展至肾损伤和儿科人群。

主要发现

  • 模型成功预测了阿哌沙班单独及在相互作用药物影响下的药代动力学。
  • 肾损伤各 impairment 组的倍数变化被成功预测,抑制性DDI与肾损伤对阿哌沙班暴露增加有协同效应,例如酮康唑联合严重肾损伤组AUC增加近3倍。
  • 小于1岁婴儿中,阿哌沙班暴露随体重归一化清除率增加而降低;新生儿AUC比1岁以上儿童高2倍以上。
  • 小于1岁婴儿中药物相互作用效应似乎减弱,而肾损伤效应可能增强。

临床怎么用

  • 可利用PBPK模型估计特殊人群(肾损伤、儿科、复杂DDI情况)首次使用阿哌沙班的剂量调整,以提高临床实践安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To develop a physiologically based pharmacokinetic (PBPK) model for apixaban, an oral anticoagulant with a narrow therapeutic index, and to predict PK profiles and potential drug-drug interactions (DDIs) in patients with renal impairment and paediatrics. METHODS: A whole-body apixaban PBPK model was developed and validated in SimCYP for healthy adults with or without interacting drugs. The model was extended to renal impairment and paediatrics. Observed PK data in adults were compared with predicted data. The effect of renal function, age and DDIs on apixaban PK was investigated. RESULTS: The PBPK model successfully predicted the PK of apixaban alone and under the influence of interacting drugs. For patients with renal impairment, the PBPK model successfully predicted the fold change in each impairment group; inhibitory DDI and renal impairment had a synergistic effect on the increase of apixaban exposure (e.g., almost 3-fold increase of AUC in ketoconazole + severe renal impairment group). For infants younger than 1 year, the exposure of apixaban decreased with increased weight-normalized clearance. For newborn infants, AUC of apixaban was >2-fold higher than that in children older than 1 year. Meanwhile, the effect of DDI seems to be weakened while the effect of renal impairment might be enhanced in infants younger than 1 year. CONCLUSION: Our study provides a reasonable approach to estimate the dose adjustment for the first use of apixaban in special populations with complex situations, which has the opportunity to make the clinical practice much safer.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xu R, Tang H, Chen L, et al. Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. Br J Clin Pharmacol. 2021. PMID: 33528059. doi:10.1111/bcp.14743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。